Nagai M
Dept. of Neurosurgery, Dokkyo University School of Medicine.
Gan To Kagaku Ryoho. 1991 Feb;18(2):188-94.
The cooperative study on the beta-interferon (IFN) therapy for glioblastoma and malignant astrocytoma reported the response rate as 14.0%. Continuing study resulted the response rate of 24.0% to low grade astrocytoma and 20.0% to medulloblastoma. Totally, effectiveness of 19.2% to gliomas was confirmed in 120 evaluated cases. A randomized study was conducted on combination therapy with beta-interferon and chemoradiotherapy. The response rate of 41.2% (21/51) in the group treated with IFN, ACNU and Radiation was significantly higher than the rate of 19.6% (10/51) in the group treated with ACNU and radiation only. Application of IFN to a maintenance therapy is also on going. Adoptive immunotherapy has been developed as potential therapeutic method of malignant glioma. Lymphokine activated killer cells (LAK) and Tumor infiltrating lymphocytes (TIL) are put to clinical use. Clinical application of human monoclonal antibody (MAb) CLN-IgG was conducted to recurrent malignant glioma. 131I labeled MAb was administered intratumorously and the specific incorporation was confirmed by gamma-scintigraphy. Concomitant administration of interferon enhanced the efficacy of the therapy. This radio-immunotherapy holds future promise as a new therapeutic approach to gliomas.
一项关于β-干扰素（IFN）治疗胶质母细胞瘤和恶性星形细胞瘤的合作研究报告称缓解率为14.0%。后续研究显示，低级别星形细胞瘤的缓解率为24.0%，髓母细胞瘤的缓解率为20.0%。在120例评估病例中，共证实对胶质瘤的有效率为19.2%。开展了一项关于β-干扰素与放化疗联合治疗的随机研究。接受IFN、ACNU和放疗治疗的组的缓解率为41.2%（21/51），显著高于仅接受ACNU和放疗治疗的组的19.6%（10/51）。IFN用于维持治疗的研究也在进行中。过继性免疫疗法已被开发为恶性胶质瘤的潜在治疗方法。淋巴因子激活的杀伤细胞（LAK）和肿瘤浸润淋巴细胞（TIL）已投入临床使用。对复发性恶性胶质瘤进行了人单克隆抗体（MAb）CLN-IgG的临床应用。将131I标记的单克隆抗体瘤内注射，并通过γ闪烁扫描证实其特异性摄取。同时给予干扰素可增强治疗效果。这种放射免疫疗法作为一种新的胶质瘤治疗方法具有广阔前景。
